Document:

Exhibit 10.33  

[ENTREMED LOGO]  

www.entremed.com 

August 23,
2006 

	 
	 	 

	Affymax, Inc.

4001 Miranda Avenue

Palo Alto, California 94304
	Attn:	 	Robert Naso, Ph.D.

Executive Vice President, R&D

	Re:
	Fifth Extension of Letter Agreement

Dear
Bob: 

        I
am writing with reference to the Letter Agreement between Affymax, Inc. ("Affymax") and EntreMed, Inc. ("EntreMed") dated as of September 20, 2004 (together with each of the
exhibits thereto, the "Letter Agreement") and the related First Extension Letter dated as of August 23, 2005 between Affymax and EntreMed (the "First Extension Letter"), pursuant to which
EntreMed and Affymax agreed to extend the Term of the Letter Agreement to December 31, 2005, and the subsequent Second Extension Letter dated as of December 19, 2005 between Affymax and
EntreMed (the "Second Extension Letter"), pursuant to which EntreMed and Affymax agreed to further extend the Term of the Letter Agreement to February 28, 2006, and the subsequent Third
Extension Letter dated as of February 28, 2006 between Affymax and EntreMed (the "Third Extension Letter"), pursuant to which EntreMed and Affymax agreed to further extend the Term of the
Letter Agreement to May 31, 2006, and the subsequent Fourth Extension Letter dated as of May 24, 2006 between Affymax and EntreMed (the "Fourth Extension Letter"), pursuant to which
EntreMed and Affymax agreed to further extend the Term of the Letter Agreement to August 31, 2006. All capitalized terms used but not defined herein shall have the meaning given to such terms
in the Letter Agreement. 

        As
both parties would like to continue the Research Collaboration under the Letter Agreement, pending our current negotiations relating to a Co-Development Agreement, the Term of the
Letter Agreement is agreed to be further extended until November 30, 2006. Both Affymax and EntreMed acknowledge and agree that, except as otherwise set forth in herein, all terms and
conditions of the Letter Agreement, the First Extension Letter, the Second Extension Letter, the Third Extension Letter and the Fourth Extension Letter would remain unchanged and in full force and
effect. 

        Please
confirm your agreement to extend the Terms of the Letter Agreement (including, without limitation, the period to enter into a Co-Development Agreement) to November 30,
2006, by countersigning this Letter and returning the countersigned letter to EntreMed. 

	 
	 
	 

	 	Very truly yours,
	

 	

EntreMed, Inc.
	

 	

By:	

/s/  MARC CORRADO      

	 	Name:	Marc Corrado
	 	Title:	Vice President Corporate Development

	 
	 
	 	 

	ACCEPTED AND AGREED:	 	 
	

Affymax, Inc.	
 	

 
	

By:	

/s/  ROBERT B. NASO      
	
 	

 
	Name:	Robert B. Naso	 	 
	Title:	Exec. V.P.	 	 
	Date:	28 Aug 2006Exhibit 10.34  

[ENTREMED
Letterhead] 

	Affymax, Inc.

4001 Miranda Avenue

Palo Alto, California 94304	 	November 27, 2006
	Attn:	 	Robert Naso, Ph.D.,

Executive Vice President, R&D	 	 
	

Re:	
 	
Sixth Extension of Letter Agreement	
 	

 

Dear
Bob: 

        I
am writing with reference to the Letter Agreement between Affymax, Inc. ("Affymax") and EntreMed, Inc. ("EntreMed") dated as of September 20, 2004 (together with each of the
exhibits thereto, as amended, the "Letter Agreement") and the related First Extension Letter dated as of August 23, 2005 between Affymax and EntreMed (the "First Extension Letter"), pursuant to
which EntreMed and Affymax agreed to extend the Term of the Letter Agreement to December 31, 2005, and the subsequent Second Extension Letter dated as of December 19, 2005 between
Affymax and EntreMed (the "Second Extension Letter"), pursuant to which EntreMed and Affymax agreed to further extend the Term of the Letter Agreement to February 28, 2006, and the subsequent
Third Extension Letter dated as of February 28, 2006 between Affymax and EntreMed (the "Third Extension Letter"), pursuant to which EntreMed and Affymax agreed to further extend the Term of the Letter
Agreement to May 31, 2006, and the subsequent Fourth Extension Letter dated as of May 24, 2006 between Affymax and EntreMed (the "Fourth Extension Letter"), pursuant to which EntreMed
and Affymax agreed to further extend the Term of the Letter Agreement to August 31, 2006, and the subsequent Fifth Extension Letter dated as of August 23, 2006 between Affymax and
EntreMed (the "Fifth Extension Letter"), pursuant to which EntreMed and Affymax agreed to further extend the Term of the Letter Agreement to November 30, 2006. All capitalized terms used but
not defined herein shall have the meaning given to such terms in the Letter Agreement. 

        As
both parties would like to continue the Research Collaboration under the Letter Agreement, pending our current negotiations relating to a Co-Development Agreement, the Term of the
Letter Agreement is agreed to be further extended until February 28, 2007. Both Affymax and EntreMed acknowledge and agree that, except as otherwise set forth in herein, all terms and
conditions of the Letter Agreement, the First Extension Letter, the Second Extension Letter, the Third Extension Letter, the Fourth Extension Letter and the Fifth Extension Letter would remain
unchanged and in full force and effect. 

        Please
confirm your agreement to extend the Term of the Letter Agreement (including, without limitation, the period to enter into a Co-Development Agreement) to February 28, 2007,
by countersigning this Letter and returning the countersigned letter to EntreMed. 

	 	 	Very truly yours,
	

 	
 	

EntreMed, Inc.
	

 	
 	

By:	

/s/  MARC CORRADO      
 Name: Marc Corrado

Title: Vice President Corporate Development

	ACCEPTED AND AGREED:	 	 
	

Affymax, Inc.	
 	

 
	

By:	

/s/  CHRISTOPHER DAMMANN      
 Name: Christopher Dammann

Title: Vice President Business Development

Date: November 28th, 2006	
 	

 

EntreMed,
Inc. / 9640 Medical Center Drive / Rockville, MD 20850

240.864.2600 phone / 240.864.2601 faxFiled by Automated Filing Services Inc. (604) 609-0244 - Luora Healthcare Systems Inc. - Exhibit 10.6

DIRECTOR AND CFO SERVICES AGREEMENT

THIS AGREEMENT (“Agreement”) made the 30th day of
November, 2006 (the “Effective Date”).

BETWEEN:

Lusora Healthcare Systems Inc.,
a public company incorporated
under the laws of the State of Nevada having
its head office at 2802

  Flintrock Trace, Suite 221 Austin, TX 78738 USA 

(the “Company”) 

AND: 

Julian Lee, a businessman with
an address at 30 Roland Gardens, 
London, SW7 3PL, UK 

(the “Executive Director”)

WHEREAS: 

A. The Company is engaged in, among other things, wireless
security and healthcare technology (the “Business”); and 

B. The Company seeks to receive services from the Executive
Director as a Director and Chief Financial Officer (“CFO”), and the Executive
Director seeks to provide such services to the Company under the terms and
conditions contained herein;

NOW THEREFORE THIS AGREEMENT WITNESSES that in consideration of
the mutual covenants and promises set forth herein, and for other good and
valuable consideration, the receipt and sufficiency of which is hereby
acknowledged by each, the parties hereto agree as follows: 

ARTICLE 1 

  APPOINTMENT

1.1 Appointment of Director and CFO. The Company hereby
agrees to appoint the Executive Director as a member of its Board (the “Board”)
and as its CFO and the Executive Director hereby agrees, upon appointment, to
provide the services set out in Article 2 hereof to the Company upon the terms
of this Agreement. The term of this Agreement (the “Term”) will commence on
December 1, 2006, which date will be deemed the “Effective Date”.

ARTICLE 2 

  DIRECTOR AND CFO SERVICES

2.1 Director Services. Upon appointment, the Executive
Director shall be a member of the Board, participate in meetings of the Board,
and otherwise provide the Company with services in accordance with best
practices of board governance for public companies from time to time. 

- 2 -

2.2 CFO Services. The Executive Director shall use his
best efforts to perform the duties of CFO and all of the duties customarily
performed by those holding similar positions in like businesses, and agrees to
provide at least 25 days of services per annum, notwithstanding time
requirements for section 2.1 herein, and public holidays. 

2.3 Additional Services. The Executive Director
acknowledges that the services of the Executive 

Director will be requested from time to time in or outside
scheduled meetings and the Executive Director may be called upon, sometimes on
short notice, to provide such services for specific concerns or issues that face
the Company.

2.4 Independent Advice. The Executive Director may, if
necessary in connection with the performing of his duties hereunder, take
independent professional advice at the Company’s expense, subject to having
first notified the Board.

ARTICLE 3

  EXPENSES

3.1 Expense Statements. The Executive Director may incur
expenses in the name of the Company as agreed in advance in writing by the
Company, as the case may be, such expenses to relate solely to the carrying out
of the Executive Director’s duties as a member of the Board and as a CFO. The
Executive Director will immediately forward all invoices for expenses incurred
on behalf of and in the name of the Company and the Company agrees to pay said
invoices directly on a timely basis. Any expenses of $500 or greater incurred by
the Executive Director in connection with the carrying out of the Executive
Director’s duties as a member of the Boards and as a CFO must be pre-approved by
the Company in writing or by email. 

ARTICLE 4 

  COMPENSATION

4.1 Fee. The Company shall pay to the Executive Director
US$3,000 per month (the “Fee”), exclusive of bonuses if any as determined by the
directors. The Fee shall be payable quarterly, in arrears, commencing December
31, 2006. 

4.2 Stock Options. The Company shall grant to the
Executive Director stock options of the common stock (the “Stock Options”), as
determined by the Board in its discretion, according to a Stock Option agreement
to be executed between the Company and the Executive Director on a date
following the execution of this Agreement.

4.3 Executive Director’s Acknowledgements. The Executive
Director acknowledges that the Options and the shares of common stock underlying
the Options may not be registered under the United States Securities Act
of 1933 (the “1933 Act”), or under any state securities or “blue sky” laws of
any state of the United States, and, unless so registered, may not be offered or
sold in the United States or to U.S. persons, except pursuant to an effective
registration statement under the 1933 Act, pursuant to an exemption from, or in
a transaction not subject to, the registration requirements of the 1933 Act and
only in accordance with all applicable securities laws. 

ARTICLE 5 

  DURATION, TERMINATION AND DEFAULT

5.1 Termination. This Agreement is deemed effective on
December 1, 2006 and will continue in force and effect until terminated by
either party. Either party shall be entitled, at any time, to terminate

- 3 -

this Agreement upon written notice delivered to the other party
in accordance with the terms hereof. The Company shall reimburse any expenses
incurred as required by this Agreement prior to the delivery of such notice. All
unvested options of the Executive Director will terminate immediately upon the
termination of this Agreement by any party. 

5.2 Duties Upon Termination. Upon termination of this
Agreement, the Executive Director shall promptly deliver the following in
accordance with the directions of the Company: 

	 	(a) 	
      a final accounting, reflecting the balance of expenses
      incurred on behalf of the Company as of the date of termination;
  and

	 	 	 
	 	(b) 	
      all documents pertaining to the Company or this
      Agreement, including but not limited to, all books of account,
      correspondence and contracts.

ARTICLE 6 

  FIDUCIARY OBLIGATIONS

6.1 Director responsibilities. As a director of a public
company, the Executive Director acknowledges that he is to act in the best
interests of the Company and owes it a fiduciary duty as a director, to use his
experience and judgement for its best interests, to act honestly and in good
faith. 

ARTICLE 7 

  MISCELLANEOUS

7.1 Notices. All notices required or allowed to be given
under this Agreement shall be made either personally by delivery to or by
facsimile or email transmission to the address as hereinafter set forth or to
such other address as may be designated from time to time by such party in
writing: 

	 	(a) 	
      in the case of the Company to:

	 	 	 
	 		
      Lusora Healthcare Systems Inc.

	 		
      2802 Flintrock Trace, Suite 221 Austin, TX 78738
    USA

	 	 	 
	 		
      Attention: Dan Bauer

	 	 	 
	 		
      Fax No: (415) 276-6314 

	 	 	Email: dbauer@lusora.com
	 	 	 
	 		
      and in the case of the Executive Director, to

	 	 	 
	 		
      Julian Lee

	 	 	30 Roland Gardens
	 		
      London SW7 3PL 

	 	 	United Kingdom
	 	 	 
	 		
      Email: julian@meleevm.com

	 	 	 
	 	(b) 	
      Change of Address. Any party may, from time to
      time, change its address for service hereunder by written notice to the
      other party in the manner aforesaid.

- 4 -

7.2 Entire Agreement. As of the date hereof, any and all
previous agreements, written or oral between the parties hereto or on their
behalf relating to the appointment of the Executive Director by the Company are
null and void. The parties hereto agree that they have expressed herein their
entire understanding and agreement concerning the subject matter of this
Agreement and it is expressly agreed that no implied covenant, condition, term
or reservation or prior representation or warranty shall be read into this
Agreement relating to or concerning the subject matter hereof or any matter or
operation provided for herein. 

7.3 Further Assurances. Each party hereto will promptly
and duly execute and deliver to the other party such further documents and
assurances and take such further action as such other party may from time to
time reasonably request in order to more effectively carry out the intent and
purpose of this Agreement and to establish and protect the rights and remedies
created or intended to be created hereby. 

7.4 Waiver. No provision hereof shall be deemed waived
and no breach excused, unless such waiver or consent excusing the breach is made
in writing and signed by the party to be charged with such waiver or consent. A
waiver by a party of any provision of this Agreement shall not be construed as a
waiver of a further breach of the same provision. 

7.5 Indemnity. The Company shall fully indemnify the
Executive Director for all losses, costs and expenses in relation to amounts
suffered or incurred as a result of carrying out his duties as a director or a
CFO of the Company and/or resulting directly or indirectly from his holding of
office as a director or a CFO of the Company. 

7.6 Amendments in Writing. No amendment, modification or
rescission of this Agreement shall be effective unless set forth in writing and
signed by the parties hereto. 

7.7 Assignment. Except as herein expressly provided, the
respective rights and obligations of the Executive Director and the Company
under this Agreement shall not be assignable by either party without the written
consent of the other party and shall, subject to the foregoing, enure to the
benefit of and be binding upon the Executive Director and the Company and their
permitted successors or assigns. Nothing herein expressed or implied is intended
to confer on any person other than the parties hereto any rights, remedies,
obligations or liabilities under or by reason of this Agreement. 

7.8 Severability. In the event that any provision
contained in this Agreement shall be declared invalid, illegal or unenforceable
by a court or other lawful authority of competent jurisdiction, such provision
shall be deemed not to affect or impair the validity or enforceability of any
other provision of this Agreement, which shall continue to have full force and
effect. 

7.9 Headings. The headings in this Agreement are
inserted for convenience of reference only and shall not affect the construction
or interpretation of this Agreement.

7.10 Number and Gender. Wherever the singular or
masculine or neuter is used in this Agreement, the same shall be construed as
meaning the plural or feminine or a body politic or corporate and vice versa
where the context so requires. 

7.11 Governing Law. This Agreement shall be construed
and interpreted in accordance with the laws of the England, and each of the
parties hereto expressly submits to the jurisdiction of the English courts. 

- 5 -

IN WITNESS WHEREOF, the parties have duly executed this
Agreement as of the day and year first above written. 

LUSORA HEALTHCARE SYSTEMS INC.

 

	Per: 	  	  
	Authorized Signatory 	  	  
	Name of Signatory: Dan Bauer 	  	  
	Title of Signatory: Director 	  	  
	 	  	  
	 	  	  
	EXECUTED by Julian Lee in the presence of:
	) 	  
	 	) 	  
	 	) 	  
	Signature 	) 	  
	 	) 	  
	Print Name 	) 	 
    
	 	) 	JULIAN LEE 
	Address 	) 	  
	 	) 	  
	 	) 	  
	 	) 	  
	Occupation 	) 	  
	 	)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00114-of-00352.parquet"}]]